GEN News Highlights

Scil, Almac Separately Report New Contract Manufacturing Deals

(Page
1
of
1)

Scil Proteins and Almac separately announced new contract manufacturing agreements. Scil’s deal is centered on the supply of the recombinant plaminogen activator Reteplase to Actavis. Reteplase is the active ingredient in the thrombolytic drug Rapilysin™, used to treat myocardial infarction. Actavis owns rights to the Reteplase production process, and distributes Rapilysin worldwide, except in the U.S. and Canada. Roche originally transferred technology and know-how for the production of recombinant plasminogen activator to Scil Proteins in 2008.

Almac will manufacture MGB-BP3, MGB Biopharma’s lead preclinical-stage candidate for the treatment of gram positive bacterial infections. Scotland-based MGB projects filing an IND for the DNA minor groove-binding compound during Q3 2012. The firm, which was established in 2009 to focus on DNA minor groove-binding anti-infectives, is initially developing MGB-BP3 as an orally administered product for the treatment of C. difficile infections, and is also developing an intravenous formulation of the drug for treating MRSA.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.